Compare Moderna, Inc. (MRNA) vs PulteGroup, Inc. (PHM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs PulteGroup, Inc. — how do they compare? Moderna, Inc. trades at $135.84 (market cap $56.02B), while PulteGroup, Inc. trades at $118.95 (market cap $22.87B). The key difference: Moderna, Inc. is far larger — about 2.4× PulteGroup, Inc.'s market cap, and PulteGroup, Inc. pays a 0.87% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MRNA | PHM | |
|---|---|---|
Market Cap | $56.02B | $22.87B |
Sector | Health | Consumer Cyclical |
52-Week High | $174.38 | $142.56 |
52-Week Low | $22.36 | $110.11 |
Enterprise Value | $52.17B | $23.28B |
Dividend Yield | — | 0.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $140.33, down 3.59% on the day, but maintains a bullish technical signal with support at $138 and resistance at $145. Recent positive phase 3 cancer vaccine trial results have driven significant stock appreciation, though financials show declining revenue and negative net income margins. The company has beaten EPS estimates for the last three quarters, with Q3 2026 results pending.
The outlook is mixed; promising clinical developments in oncology offer long-term growth potential, but high valuation multiples and persistent losses pose risks. Analyst consensus is cautious with a $90.08 price target below the current price, reflecting concerns over profitability and competitive pressures in the mRNA therapeutics space.
PulteGroup (PHM) trades at $120.07, down 3.52% on the day amid a bearish technical signal. The stock shows mixed fundamentals with a P/E of 12.26 and net income margin of 11.62%, but recent earnings missed expectations in two of the last three quarters. Positive cash flow of $355.10M in 2025 and expansion into Northwest Florida provide operational strength, though rising mortgage rates pose headwinds.
The outlook is cautious with analyst consensus leaning buy (47.73%) and a $137.57 price target suggesting 14.6% upside. Key risks include housing affordability pressures from higher yields and volatile earnings performance. The stock's current level near support at $119 offers a potential entry, but macroeconomic sensitivity warrants careful monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About PulteGroup, Inc.
PulteGroup Inc is one of the largest homebuilders in the United States, operating in 40 markets across 23 states. The company mainly builds single-family detached homes (85% of unit sales) and offers products to entry-level, move-up, and active-adult buyers. PulteGroup offers homebuyers mortgage financing and title agency services through its financial services segment. The company is headquartered in Atlanta.
Read more on PHM →
